Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Aug;65(2):164–169. doi: 10.1136/jnnp.65.2.164

Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains

T Counihan 1, J Penney 1
PMCID: PMC2170219  PMID: 9703165

Abstract

OBJECTIVE—To test the hypothesis that differential regional dopamine transporter (DAT) gene expression may underlie the selective vulnerability of certain nigral dopaminergic neurons in Parkinson's disease, DAT mRNA expression was examined in neuronal subpopulations of human postmortem ventral mesencephalon from patients with Parkinson's disease and controls.
METHODS—Radioactive in situ hybridisation histochemistry using a polymerase chain reaction derived ribonucleotide probe for DAT was performed on sections of ventral mesencephalon from the brains of five donors with no history of neurological illness and from five patients with pathologically established Parkinson's disease. The number of silver grains overlying melanised neurons from the paranigral nucleus, dorsal and ventral tier, and pars lateralis of the substantia nigra pars compacta were compared with each other and to background labelling by using a one way factorial analysis of variance (ANOVA) with a significance level of 5%.
RESULTS—In control brains, there was intense DAT mRNA expression in the ventral midbrain with no significant difference in mRNA concentrations among the four regions studied. In the Parkinson's disease brains, there was an overall decrease in the intensity of DAT mRNA expression in the surviving dopaminergic neurons. There were no significant differences in signal between regions in either the control or parkinsonian brains.
CONCLUSION—Taken together, these findings do not support the hypothesis that differential regional DAT gene expression underlies the selective vulnerability of certain nigral dopaminergic neurons in Parkinson's disease, as the vulnerable neurons of the substantia nigra pars compacta do not express more DAT mRNA than the resistant paranigral neurons.



Full Text

The Full Text of this article is available as a PDF (135.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amara S. G., Kuhar M. J. Neurotransmitter transporters: recent progress. Annu Rev Neurosci. 1993;16:73–93. doi: 10.1146/annurev.ne.16.030193.000445. [DOI] [PubMed] [Google Scholar]
  2. Augood S. J., Westmore K., McKenna P. J., Emson P. C. Co-expression of dopamine transporter mRNA and tyrosine hydroxylase mRNA in ventral mesencephalic neurones. Brain Res Mol Brain Res. 1993 Dec;20(4):328–334. doi: 10.1016/0169-328x(93)90059-x. [DOI] [PubMed] [Google Scholar]
  3. Bannon M. J., Poosch M. S., Xia Y., Goebel D. J., Cassin B., Kapatos G. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7095–7099. doi: 10.1073/pnas.89.15.7095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bannon M. J., Whitty C. J. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology. 1997 Apr;48(4):969–977. doi: 10.1212/wnl.48.4.969. [DOI] [PubMed] [Google Scholar]
  5. Blanchard V., Raisman-Vozari R., Vyas S., Michel P. P., Javoy-Agid F., Uhl G., Agid Y. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. Brain Res Mol Brain Res. 1994 Mar;22(1-4):29–38. doi: 10.1016/0169-328x(94)90029-9. [DOI] [PubMed] [Google Scholar]
  6. Bogerts B. A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker. J Comp Neurol. 1981 Mar 20;197(1):63–80. doi: 10.1002/cne.901970106. [DOI] [PubMed] [Google Scholar]
  7. Booij J., Tissingh G., Boer G. J., Speelman J. D., Stoof J. C., Janssen A. G., Wolters E. C., van Royen E. A. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):133–140. doi: 10.1136/jnnp.62.2.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Braak H., Braak E. Nuclear configuration and neuronal types of the nucleus niger in the brain of the human adult. Hum Neurobiol. 1986;5(2):71–82. [PubMed] [Google Scholar]
  9. Cerruti C., Walther D. M., Kuhar M. J., Uhl G. R. Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. Brain Res Mol Brain Res. 1993 Apr;18(1-2):181–186. doi: 10.1016/0169-328x(93)90187-t. [DOI] [PubMed] [Google Scholar]
  10. Ciliax B. J., Heilman C., Demchyshyn L. L., Pristupa Z. B., Ince E., Hersch S. M., Niznik H. B., Levey A. I. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci. 1995 Mar;15(3 Pt 1):1714–1723. doi: 10.1523/JNEUROSCI.15-03-01714.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fearnley J. M., Lees A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991 Oct;114(Pt 5):2283–2301. doi: 10.1093/brain/114.5.2283. [DOI] [PubMed] [Google Scholar]
  12. Gerfen C. R., Herkenham M., Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci. 1987 Dec;7(12):3915–3934. doi: 10.1523/JNEUROSCI.07-12-03915.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gibb W. R., Lees A. J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1991 May;54(5):388–396. doi: 10.1136/jnnp.54.5.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Giros B., Caron M. G. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci. 1993 Feb;14(2):43–49. doi: 10.1016/0165-6147(93)90029-j. [DOI] [PubMed] [Google Scholar]
  15. Giros B., Jaber M., Jones S. R., Wightman R. M., Caron M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996 Feb 15;379(6566):606–612. doi: 10.1038/379606a0. [DOI] [PubMed] [Google Scholar]
  16. Haber S. N., Ryoo H., Cox C., Lu W. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol. 1995 Nov 20;362(3):400–410. doi: 10.1002/cne.903620308. [DOI] [PubMed] [Google Scholar]
  17. Harrington K. A., Augood S. J., Kingsbury A. E., Foster O. J., Emson P. C. Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease. Brain Res Mol Brain Res. 1996 Feb;36(1):157–162. doi: 10.1016/0169-328x(95)00278-z. [DOI] [PubMed] [Google Scholar]
  18. Hirsch E., Graybiel A. M., Agid Y. A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 1988 Jul 28;334(6180):345–348. doi: 10.1038/334345a0. [DOI] [PubMed] [Google Scholar]
  19. Hurd Y. L., Pristupa Z. B., Herman M. M., Niznik H. B., Kleinman J. E. The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons. Neuroscience. 1994 Nov;63(2):357–362. doi: 10.1016/0306-4522(94)90535-5. [DOI] [PubMed] [Google Scholar]
  20. Javitch J. A., Uhl G. R., Snyder S. H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4591–4595. doi: 10.1073/pnas.81.14.4591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kingsbury A. E., Foster O. J., Nisbet A. P., Cairns N., Bray L., Eve D. J., Lees A. J., Marsden C. D. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res. 1995 Feb;28(2):311–318. doi: 10.1016/0169-328x(94)00219-5. [DOI] [PubMed] [Google Scholar]
  22. Kitayama S., Shimada S., Xu H., Markham L., Donovan D. M., Uhl G. R. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7782–7785. doi: 10.1073/pnas.89.16.7782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Landwehrmeyer G. B., Standaert D. G., Testa C. M., Penney J. B., Jr, Young A. B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci. 1995 Jul;15(7 Pt 2):5297–5307. doi: 10.1523/JNEUROSCI.15-07-05297.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. McRitchie D. A., Cartwright H. R., Halliday G. M. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp Neurol. 1997 Mar;144(1):202–213. doi: 10.1006/exnr.1997.6418. [DOI] [PubMed] [Google Scholar]
  25. McRitchie D. A., Halliday G. M. Calbindin D28k-containing neurons are restricted to the medial substantia nigra in humans. Neuroscience. 1995 Mar;65(1):87–91. doi: 10.1016/0306-4522(94)00483-l. [DOI] [PubMed] [Google Scholar]
  26. McRitchie D. A., Hardman C. D., Halliday G. M. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J Comp Neurol. 1996 Jan 1;364(1):121–150. doi: 10.1002/(SICI)1096-9861(19960101)364:1<121::AID-CNE11>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  27. Miller G. W., Staley J. K., Heilman C. J., Perez J. T., Mash D. C., Rye D. B., Levey A. I. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol. 1997 Apr;41(4):530–539. doi: 10.1002/ana.410410417. [DOI] [PubMed] [Google Scholar]
  28. Niznik H. B., Fogel E. F., Fassos F. F., Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem. 1991 Jan;56(1):192–198. doi: 10.1111/j.1471-4159.1991.tb02580.x. [DOI] [PubMed] [Google Scholar]
  29. Paulus W., Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. 1991 Nov;50(6):743–755. doi: 10.1097/00005072-199111000-00006. [DOI] [PubMed] [Google Scholar]
  30. Pifl C., Giros B., Caron M. G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci. 1993 Oct;13(10):4246–4253. doi: 10.1523/JNEUROSCI.13-10-04246.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ritz M. C., Lamb R. J., Goldberg S. R., Kuhar M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987 Sep 4;237(4819):1219–1223. doi: 10.1126/science.2820058. [DOI] [PubMed] [Google Scholar]
  32. Shimada S., Kitayama S., Lin C. L., Patel A., Nanthakumar E., Gregor P., Kuhar M., Uhl G. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science. 1991 Oct 25;254(5031):576–578. doi: 10.1126/science.1948034. [DOI] [PubMed] [Google Scholar]
  33. Shimada S., Kitayama S., Walther D., Uhl G. Dopamine transporter mRNA: dense expression in ventral midbrain neurons. Brain Res Mol Brain Res. 1992 May;13(4):359–362. doi: 10.1016/0169-328x(92)90220-6. [DOI] [PubMed] [Google Scholar]
  34. Sitzmann J. H., LeMotte P. K. Rapid and efficient generation of PCR-derived riboprobe templates for in situ hybridization histochemistry. J Histochem Cytochem. 1993 May;41(5):773–776. doi: 10.1177/41.5.7682230. [DOI] [PubMed] [Google Scholar]
  35. Snyder S. H., D'Amato R. J. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. Neurology. 1986 Feb;36(2):250–258. doi: 10.1212/wnl.36.2.250. [DOI] [PubMed] [Google Scholar]
  36. Uhl G. R., Hedreen J. C., Price D. L. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology. 1985 Aug;35(8):1215–1218. doi: 10.1212/wnl.35.8.1215. [DOI] [PubMed] [Google Scholar]
  37. Uhl G. R., Walther D., Mash D., Faucheux B., Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol. 1994 Apr;35(4):494–498. doi: 10.1002/ana.410350421. [DOI] [PubMed] [Google Scholar]
  38. Vandenbergh D. J., Persico A. M., Uhl G. R. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res Mol Brain Res. 1992 Sep;15(1-2):161–166. doi: 10.1016/0169-328x(92)90165-8. [DOI] [PubMed] [Google Scholar]
  39. Yamada T., McGeer P. L., Baimbridge K. G., McGeer E. G. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 1990 Sep 3;526(2):303–307. doi: 10.1016/0006-8993(90)91236-a. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES